Y0000744
Dextranomer
European Pharmacopoeia (EP) Reference Standard
Sign Into View Organizational & Contract Pricing
Select a Size
50 MG
R 2 247,14
All Photos(1)
Select a Size
Change View
50 MG
R 2 247,14
About This Item
Recommended Products
grade
pharmaceutical primary standard
API family
dextranomer
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Dextranomer EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Sorry, we don't have COAs for this product available online at this time.
If you need assistance, please contact Customer Support.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
David Ben-Meir et al.
The Journal of urology, 188(1), 258-261 (2012-05-19)
We histologically investigated the cause of failed endoscopic treatment of vesicoureteral reflux with dextranomer/hyaluronic acid injections in children. A total of 192 children underwent dextranomer/hyaluronic acid injection at our institution between January 2008 and September 2010. The study population consisted
Intermediate to long-term follow-up indicates low risk of recurrence after double HIT endoscopic treatment for primary vesico-ureteral reflux.
Ilker Akyol
Journal of pediatric urology, 8(4), 449-449 (2011-11-08)
I Alova et al.
Journal of pediatric urology, 8(1), 40-46 (2011-02-01)
To evaluate outcome of further continence procedures after failure of endoscopic injections of dextranomer-based bulking agent. From 1997, 89 children (3-18 years) and one young adult were treated for incontinence with 145 endoscopic injections of dextranomer. On evaluation, each patient
Renate Pichler et al.
Urologia internationalis, 87(2), 192-198 (2011-08-26)
We evaluated whether real-time 3D ultrasound (4D-US) together with clinical evaluation is an alternative to voiding cystourethrography (VCUG) after endoscopic treatment of vesicoureteral reflux (VUR) in children at postoperative follow-up. We reviewed 178 children who underwent endoscopic therapy with dextranomer/hyaluronic
Saburo Tanikaze et al.
Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 101(5), 676-682 (2010-08-19)
To investigate the efficacy and safety of endoscopic treatment with the injectable gel of dextranomer beads in stabilized non-animal sodium hyaluronate (NASHA/Dx gel) administered submucosally close to the proximity of ureteral orifice, we performed the multi-center open study of Japanese
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
